

## Translation

### Supplemental Approval of New Formulation of Immunosuppressant, “CellCept® Powder for Oral Suspension 31.8%”

August 17, 2015 - Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku Tokyo; Chairman & CEO: Osamu Nagayama] (hereafter, “Chugai”) announced today that it has obtained a supplemental approval from the Ministry of Health, Labour and Welfare (MHLW) for “CellCept® Powder for Oral Suspension 31.8%” (generic name: mycophenolate mofetil) (hereafter, “CellCept Powder”). CellCept Powder is a new form of “CellCept® Capsules 250,” an immunosuppressant which has been sold as the indications of “Treatment of refractory rejections after kidney transplant” and “Suppression of rejections after the following organ transplants: kidney, heart, liver, lung and pancreas transplants.”

Pediatric patients have difficulties in administration of the capsule formulation, and it is complicated to adjust dosage with the capsule formulation. Moreover, both the powder and the capsule formulations are available outside of Japan. Given these situations, Chugai filed a supplemental application of CellCept Powder in order that each patient can select different forms of CellCept according to their needs.

Chugai believes that the approval of CellCept Powder will contribute to patients’ satisfaction for the treatment. Under its business philosophy “Innovation all for the patients,” Chugai continues to make efforts toward contribution to transplantation therapy and fulfilling unmet medical needs through offering new treatment options.